Below are the most recent publications written about "Pyridines" by people in Profiles.
-
Smeets R, Pfefferle S, B?ttner H, Knobloch JK, L?tgehetmann M. Impact of Oral Rinsing with Octenidine Based Solution on SARS-CoV-2 Loads in Saliva of Infected Patients an Exploratory Study. Int J Environ Res Public Health. 2022 05 04; 19(9).
-
Santoni M, Aurilio G, Massari F, Grande E, Matrana MR, Rizzo M, De Giorgi U, Incorvaia L, Martignetti A, Molina-Cerrillo J, Zabalza IO, Mollica V, Rizzo A, Battelli N, Porta C. Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison. Clin Genitourin Cancer. 2022 06; 20(3):285-295.
-
Sharma T, Robinson DCL, Witwicka H, Dilworth FJ, Imbalzano AN. The Bromodomains of the mammalian SWI/SNF (mSWI/SNF) ATPases Brahma (BRM) and Brahma Related Gene 1 (BRG1) promote chromatin interaction and are critical for skeletal muscle differentiation. Nucleic Acids Res. 2021 08 20; 49(14):8060-8077.
-
Marchetti A, Rosellini M, Rizzo A, Mollica V, Battelli N, Massari F, Santoni M. An up-to-date evaluation of cabozantinib for the treatment of renal cell carcinoma. Expert Opin Pharmacother. 2021 Dec; 22(17):2323-2336.
-
Santoni M, Massari F, Grande E, Procopio G, Matrana MR, Rizzo M, De Giorgi U, Basso U, Milella M, Iacovelli R, Aurilio G, Incorvaia L, Buti S, Caffo O, Fornarini G, Carrozza F, Mollica V, Rizzo A, Farag F, Molina-Cerrillo J, Battelli N. Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study. Target Oncol. 2021 09; 16(5):625-632.
-
Santoni M, Rizzo A, Mollica V, Rosellini M, Marchetti A, Fragomeno B, Battelli N, Massari F. Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis. Expert Rev Pharmacoecon Outcomes Res. 2022 Jan; 22(1):45-51.
-
Mellion ML, Ronco L, Berends CL, Pagan L, Brooks S, van Esdonk MJ, van Brummelen EMJ, Odueyungbo A, Thompson LA, Hage M, Badrising UA, Raines S, Tracewell WG, van Engelen B, Cadavid D, Groeneveld GJ. Phase 1 clinical trial of losmapimod in facioscapulohumeral dystrophy: Safety, tolerability, pharmacokinetics, and target engagement. Br J Clin Pharmacol. 2021 12; 87(12):4658-4669.
-
Westhovens R, Rigby WFC, van der Heijde D, Ching DWT, Stohl W, Kay J, Chopra A, Bartok B, Matzkies F, Yin Z, Guo Y, Tasset C, Sundy JS, Jahreis A, Mozaffarian N, Messina OD, Landew? RB, Atsumi T, Burmester GR. Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. Ann Rheum Dis. 2021 06; 80(6):727-738.
-
Angheloiu AA, Tan Y, Ruse C, Shaffer SA, Angheloiu GO. In-Vitro Sorbent-Mediated Removal of Edoxaban from Human Plasma and Albumin Solution. Drugs R D. 2020 Sep; 20(3):217-223.
-
Iacovelli R, Ciccarese C, Facchini G, Milella M, Urbano F, Basso U, De Giorgi U, Sabbatini R, Santini D, Berardi R, Santoni M, Bracarda S, Massari F, Masini C, De Tursi M, Ricotta R, Buti S, Zustovich F, Sepe P, Rossetti S, Maruzzo M, Cortesi E, Tortora G, Procopio G. Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis. Target Oncol. 2020 08; 15(4):495-501.